Telix Pharmaceuticals Limited (TLX) Financial Ratios
9 years of historical data (2017–2025) · Healthcare · Biotechnology
EV/EBITDA
↓
92.82
↑+69% vs avg
5yr avg: 54.98
30Y Low50.9·High59.1
P/FCF
N/A
—
5yr avg: 185.18
30Y Low185.2·High185.2
P/B Ratio
↓
8.04
+20% vs avg
5yr avg: 6.71
30Y Low4.1·High9.4
ROE
↑
-1.8%
↓+98% vs avg
5yr avg: -87.0%
30Y Low-253%·High14%
Debt/EBITDA
↑
11.80
↑+84% vs avg
5yr avg: 6.40
30Y Low0.8·High11.8
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
TLX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Telix Pharmaceuticals Limited currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $3.5B | $2.5B | $5.3B | — | — | — | — | — | — | — |
| Enterprise Value | $3.8B | $3.0B | $5.2B | — | — | — | — | — | — | — |
| P/E Ratio → | -468.72 | — | 110.00 | — | — | — | — | — | — | — |
| P/S Ratio | 4.16 | 2.10 | 6.79 | — | — | — | — | — | — | — |
| P/B Ratio | 8.04 | 4.07 | 9.36 | — | — | — | — | — | — | — |
| P/FCF | — | — | 185.18 | — | — | — | — | — | — | — |
| P/OCF | — | — | 123.54 | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
TLX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Telix Pharmaceuticals Limited's enterprise value stands at 92.8x EBITDA, 69% above its 5-year average of 55.0x. The Healthcare sector median is 14.1x, placing the stock at a 557% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.50 | 6.62 | — | — | — | — | — | — | — |
| EV / EBITDA | 92.82 | 50.89 | 59.07 | — | — | — | — | — | — | — |
| EV / EBIT | 206.63 | 63.99 | 56.05 | — | — | — | — | — | — | — |
| EV / FCF | — | — | 180.69 | — | — | — | — | — | — | — |
TLX Profitability
Margins and return-on-capital ratios measuring operating efficiency
Telix Pharmaceuticals Limited earns an operating margin of 2.2%. A negative ROE of -1.8% indicates the company is currently destroying shareholder equity. ROIC of 2.6% represents below-average returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 53.1% | 53.1% | 65.1% | 62.6% | 59.3% | 66.5% | 61.2% | -340.7% | 100.0% | — |
| Operating Margin | 2.2% | 2.2% | 10.5% | 3.2% | -57.4% | -1069.6% | -847.7% | -1033.6% | -15016.1% | — |
| Net Profit Margin | -0.9% | -0.9% | 6.4% | 1.0% | -65.0% | -1059.9% | -861.1% | -799.6% | -7087.1% | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -1.8% | -1.8% | 13.9% | 4.6% | -253.3% | -198.4% | -60.2% | -45.3% | -27.1% | -12.9% |
| ROA | -0.7% | -0.7% | 5.2% | 1.6% | -57.0% | -60.2% | -34.5% | -31.1% | -21.6% | -12.5% |
| ROIC | 2.6% | 2.6% | 25.5% | 137.8% | — | — | -214.6% | -95.7% | -147.8% | — |
| ROCE | 2.0% | 2.0% | 11.5% | 7.7% | -76.1% | -77.5% | -38.5% | -44.9% | -49.6% | -13.1% |
TLX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Telix Pharmaceuticals Limited carries a Debt/EBITDA ratio of 11.8x, which is highly leveraged (265% above the sector average of 3.2x). Net debt stands at $487M ($700M total debt minus $213M cash). Interest coverage of just 0.9x is concerning — the company has limited headroom to absorb earnings volatility before struggling with debt service.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.12 | 1.12 | 1.02 | 0.12 | 0.13 | 1.18 | 0.03 | 0.03 | 0.03 | 0.01 |
| Debt / EBITDA | 11.80 | 11.80 | 6.62 | 0.77 | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.78 | -0.23 | -0.71 | -1.32 | -9.04 | -0.96 | -0.61 | -0.45 | -0.98 |
| Net Debt / EBITDA | 8.22 | 8.22 | -1.47 | -4.68 | — | — | — | — | — | — |
| Debt / FCF | — | — | -4.49 | -7.45 | — | — | -44.24 | — | — | — |
| Interest Coverage | 0.86 | 0.86 | 4.31 | 1.81 | -241.91 | -384.54 | -37.61 | -11.92 | -1009.81 | -604.57 |
TLX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.43x means Telix Pharmaceuticals Limited can comfortably meet its short-term obligations, though there is limited excess liquidity.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.43 | 1.43 | 2.78 | 1.43 | 2.02 | 1.25 | 4.69 | 5.52 | 4.35 | 33.74 |
| Quick Ratio | 1.27 | 1.27 | 2.66 | 1.32 | 1.96 | 1.16 | 4.66 | 5.47 | 4.27 | 33.74 |
| Cash Ratio | 0.61 | 0.61 | 2.15 | 0.78 | 1.36 | 0.58 | 3.91 | 4.20 | 3.13 | 33.20 |
| Asset Turnover | — | 0.68 | 0.52 | 1.26 | 0.63 | 0.07 | 0.03 | 0.03 | 0.00 | — |
| Inventory Turnover | 10.17 | 10.17 | 7.17 | 10.87 | 11.30 | 11.20 | 3.20 | 28.34 | — | — |
| Days Sales Outstanding | — | 62.77 | 74.10 | 57.77 | 71.00 | 1001.64 | 993.62 | 1362.49 | 16778.73 | — |
TLX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Telix Pharmaceuticals Limited does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 0.9% | — | — | — | — | — | — | — |
| FCF Yield | — | — | 0.5% | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — | — |
| Shares Outstanding | — | $338M | $345M | $324M | $311M | $282M | $257M | $233M | $202M | $128M |
Peer Comparison
Compare TLX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 TLXYou | $3B | -468.7 | 92.8 | — | 53.1% | 2.2% | -1.8% | 2.6% | 11.8 |
 EXEL | $13B | 18.5 | 14.1 | 15.4 | 96.4% | 37.6% | 35.5% | 32.1% | 0.2 |
 RNW | $2B | 19.7 | 10.3 | — | 58.5% | 43.4% | 8.0% | 5.4% | 8.6 |
 AGEN | $128M | -902.9 | — | — | 29.6% | -18.0% | — | — | — |
 LNTH | $7B | 31.1 | 17.2 | 19.5 | 61.1% | 20.2% | 21.4% | 30.6% | 0.0 |
 NVS | $293B | 21.3 | 14.2 | 16.5 | 75.0% | 31.2% | 31.0% | 18.8% | 1.7 |
 BMY | $113B | 16.1 | 9.1 | 8.8 | 67.6% | 26.3% | 40.4% | 16.9% | 2.8 |
 PRAX | $9B | -22.7 | — | — | — | — | -45.8% | -65.0% | — |
 GE | $372B | 43.7 | 38.1 | 51.3 | 36.8% | 19.1% | 45.3% | 24.7% | 2.1 |
 GEHC | $29B | 14.0 | 10.3 | 19.2 | 40.0% | 13.4% | 21.6% | 13.3% | 3.0 |
 SYK | $119B | 36.9 | 21.6 | 27.7 | 64.0% | 19.5% | 15.1% | 11.1% | 2.7 |
| Healthcare Median | — | 22.0 | 14.1 | 18.7 | 63.6% | -4.8% | -32.4% | -11.2% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 9 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
TLX — Frequently Asked Questions
Quick answers to the most common questions about buying TLX stock.
What is Telix Pharmaceuticals Limited's P/E ratio?
Telix Pharmaceuticals Limited's current P/E ratio is -468.7x. The historical average is 110.0x.
What is Telix Pharmaceuticals Limited's EV/EBITDA?
Telix Pharmaceuticals Limited's current EV/EBITDA is 92.8x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 55.0x.
What is Telix Pharmaceuticals Limited's ROE?
Telix Pharmaceuticals Limited's return on equity (ROE) is -1.8%. The historical average is -64.5%.
Is TLX stock overvalued?
Based on historical data, Telix Pharmaceuticals Limited is trading at a P/E of -468.7x. Compare with industry peers and growth rates for a complete picture.
What are Telix Pharmaceuticals Limited's profit margins?
Telix Pharmaceuticals Limited has 53.1% gross margin and 2.2% operating margin.
How much debt does Telix Pharmaceuticals Limited have?
Telix Pharmaceuticals Limited's Debt/EBITDA ratio is 11.8x, indicating high leverage. A ratio above 4x may signal elevated financial risk.